Search Result

Search Result

Results for "

M2-like macrophages

" in MedChemExpress (MCE) Product Catalog:

標的別:	Akt (1) AMPK (1) Apoptosis (3) c-Fms (2) CCR (2) Drug Derivative (3) Endogenous Metabolite (1) HDAC (1) MAPKAPK2 (MK2) (1) mTOR (1) NF-κB (1) p38 MAPK (1) Prostaglandin Receptor (1) Reactive Oxygen Species (ROS) (1) Reference Standards (1) STAT (2) VEGFR (3)
研究分野別:	Cancer (11) Endocrinology (1) Inflammation/Immunology (5) Metabolic Disease (1) Neurological Disease (1)

12

阻害剤およびアゴニスト

3

ペプチド

1

阻害性抗体

1

天然物

製品番号	製品名	Target	研究分野	構造式

Icrucumab 1 Publications Verification Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1	VEGFR Apoptosis p38 MAPK Akt	Endocrinology Cancer
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is an IgG1 antibody inhibitor targeting VEGFR-1/FLT1 with anti-tumor activity. By blocking ligand-dependent phosphorylation and downstream signal transduction, Icrucumab reduces the activities of MAPK and Akt in breast cancer xenograft models, inhibits the proliferation and invasion of VEGFR-1-positive tumor cells, and reverses the conversion of M1 macrophages to the pro-tumor M2-like phenotype. Icrucumab also inhibits tumor cell proliferation, promotes apoptosis, and effectively suppresses tumor growth through direct targeting of tumors and host support mechanisms. In addition, Icrucumab exhibits a synergistic effect when combined with chemotherapeutic agents, and it is used in research related to various cancers including advanced solid malignancies, thyroid cancer, melanoma, and lung cancer .

Medrysone 1 Publications Verification HMS; 6α-Methyl-11β-hydroxyprogesterone	VEGFR CCR STAT	Neurological Disease
Medrysone (HMS; 6α-Methyl-11β-hydroxyprogesterone) is a STAT6 modulator and M2 macrophage polarization inducer. Medrysone enhances IL-4-triggered STAT6 activation, upregulates the expression of M2 markers, and promotes the secretion of VEGF and CCL2. Medrysone also enhances the pro-migratory activity of M2-like macrophages toward endothelial cells. By regulating macrophage polarization and related repair pathways, Medrysone significantly promotes corneal wound repair in a rat mechanical injury model. Medrysone can be used for research related to corneal injury .

ITF 3756	HDAC NF-κB	Cancer
ITF 3756 is a selective, orally active HDAC6 inhibitor. ITF 3756 antagonizes TNF-α-induced activation of the NF-κB pathway. ITF 3756 reduces PD-L1 expression on human monocytes and CD8 ⁺ T cells, and exhibits antitumor activity. ITF 3756 can be used in colon cancer-related research .

RP-182-PEG3-K(palmitic acid)-NH2	Drug Derivative	Cancer
RP-182-PEG3-K palmitic acid-NH2 (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid-NH2 inhibits CD206 ^high M2-like macrophage (IC₅₀ of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid-NH2 exhibits antitumor efficacy in mouse B16 melanoma allografts .

CSF1R-IN-3 1 Publications Verification	c-Fms	Cancer
CSF1R-IN-3 (compound 21) is a potent and orally active CSF-1R inhibitor (IC₅₀=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity .

Momordicoside G Momordicacoside G	Endogenous Metabolite Reactive Oxygen Species (ROS) Apoptosis	Inflammation/Immunology Cancer
Momordicoside G (Momordicacoside G) is an orally active cucurbitane-type triterpene glycoside. Momordicoside G selectively induces apoptosis of M1-like macrophages, without affecting M2-like macrophages. Momordicoside G reduces intracellular ROS levels and promotes autophagy. Momordicoside G also has anticancer activity, inhibiting the growth of cancer cell lines. Momordicoside G stimulates M2-associated lung injury repair and prevents inflammatory lung cancer injury .

RP-182-PEG3-K(palmitic acid)-NH2 TFA	Drug Derivative	Cancer
RP-182-PEG3-K(palmitic acid)-NH2 (Compound 1a) TFA is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K(palmitic acid)-NH2 TFA inhibits CD206 ^high M2-like macrophage (IC₅₀ of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K(palmitic acid)-NH2 TFA exhibits antitumor efficacy in mouse B16 melanoma allografts .

MK2-IN-6	MAPKAPK2 (MK2)	Inflammation/Immunology Cancer
MK2-IN-6 (Compound 11) is a potent and selective irreversible MK2 inhibitor with an IC₅₀ value of 2.3 nM. MK2-IN-6 inhibits MK2 kinase activity, achieving prolonged MK2 signaling suppression and reducing pathological inflammatory cytokines in macrophages. MK2-IN-6 inhibits the M2-like protumor phenotype of macrophages both in vitro and in vivo, which is proming for research of colorectal cancer .

Medrysone (Standard) HMS (Standard); 6α-Methyl-11β-hydroxyprogesterone (Standard)	Reference Standards STAT VEGFR CCR	Inflammation/Immunology
Medrysone (Standard) is the analytical standard of Medrysone. This product is intended for research and analytical applications. Medrysone (HMS; 6α-Methyl-11β-hydroxyprogesterone) is a STAT6 modulator and M2 macrophage polarization inducer. Medrysone enhances IL-4-triggered STAT6 activation, upregulates the expression of M2 markers, and promotes the secretion of VEGF and CCL2. Medrysone also enhances the pro-migratory activity of M2-like macrophages toward endothelial cells. By regulating macrophage polarization and related repair pathways, Medrysone significantly promotes corneal wound repair in a rat mechanical injury model. Medrysone can be used for research related to corneal injury .

CSF1R-IN-22	c-Fms Apoptosis	Cancer
CSF1R-IN-22 (Compound C19) is an orally effective CSF-1R selective inhibitor (IC₅₀<6 nM). CSF1R-IN-22 enhances the secretion of CXCL9 from M2 macrophages, increases CD8 ⁺ T cell infiltration. CSF1R-IN-22 boosts anti-tumor immune responses of anti-PD-1, and induces apoptosis in tumor cells. CSF1R-IN-22 can effectively reprogram M2-like TAMs (tumor-associated macrophages) to the M1 phenotype and reshape the TME by inducing the recruitment of CD8 ⁺ T cells into tumors and reducing the infiltration of immunosuppressive Tregs and MDSCs .

HTL0039732	Prostaglandin Receptor	Cancer
HTL0039732 is an orally active antagonist of the prostaglandin EP4 receptor (Prostaglandin E2 Receptor EP4). HTL0039732 reverses PGE₂-induced differentiation toward M2-like macrophages. HTL0039732 exhibits efficacy in syngeneic tumor models and acts synergistically with PD-1/PD-L1 pathway blockers. HTL0039732 can be used for the research of advanced solid tumors .

AMPK/mTOR modulator-1	Drug Derivative mTOR AMPK	Metabolic Disease Inflammation/Immunology Cancer
AMPK/mTOR modulator-1, Ginsenoside derivative, is an orally active mTOR inhibitor and AMPK activator. AMPK/mTOR modulator-1 activates AMPK signaling with a K_d of 4.759 μM. AMPK/mTOR modulator-1 promotes M1-like tumor-associated macrophage polarization while suppressing M2-like polarization. AMPK/mTOR modulator-1 can enhance glycolysis. AMPK/mTOR modulator-1 significantly inhibits tumor progression and shows anti-inflammation activity. AMPK/mTOR modulator-1 can be used for the research of colorectal cancer .

製品番号	製品名	Target	研究分野

M2 Peptide	ペプチド	Inflammation/Immunology Cancer
M2 Peptide is a peptide targeting M2-like tumor-associated macrophages (TAMs). M2 Peptide is used to carry drugs or small interfering RNA (siRNA) to promote the repolarization of M2-like macrophages to M1-like macrophages, thereby altering the immunosuppressive state in the tumor microenvironment and enhancing the anti-tumor immune response. M2 Peptide can be used to study the effect of macrophage polarization and how this polarization change affects tumor growth and metastasis .

RP-182-PEG3-K(palmitic acid)-NH2	Drug Derivative	Cancer
RP-182-PEG3-K palmitic acid-NH2 (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid-NH2 inhibits CD206 ^high M2-like macrophage (IC₅₀ of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid-NH2 exhibits antitumor efficacy in mouse B16 melanoma allografts .

RP-182-PEG3-K(palmitic acid)-NH2 TFA	Drug Derivative	Cancer
RP-182-PEG3-K(palmitic acid)-NH2 (Compound 1a) TFA is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K(palmitic acid)-NH2 TFA inhibits CD206 ^high M2-like macrophage (IC₅₀ of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K(palmitic acid)-NH2 TFA exhibits antitumor efficacy in mouse B16 melanoma allografts .

製品番号	製品名	Target	研究分野	Image

Icrucumab 1 Publications Verification Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1	VEGFR Apoptosis p38 MAPK Akt	Endocrinology Cancer
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is an IgG1 antibody inhibitor targeting VEGFR-1/FLT1 with anti-tumor activity. By blocking ligand-dependent phosphorylation and downstream signal transduction, Icrucumab reduces the activities of MAPK and Akt in breast cancer xenograft models, inhibits the proliferation and invasion of VEGFR-1-positive tumor cells, and reverses the conversion of M1 macrophages to the pro-tumor M2-like phenotype. Icrucumab also inhibits tumor cell proliferation, promotes apoptosis, and effectively suppresses tumor growth through direct targeting of tumors and host support mechanisms. In addition, Icrucumab exhibits a synergistic effect when combined with chemotherapeutic agents, and it is used in research related to various cancers including advanced solid malignancies, thyroid cancer, melanoma, and lung cancer .

製品番号	製品名	Category	Target	構造式

Momordicoside G Momordicacoside G	Triterpenes Terpenoids Cucurbitaceae Plants Source Classification Momordica charantia Linn.	Endogenous Metabolite Reactive Oxygen Species (ROS) Apoptosis
Momordicoside G (Momordicacoside G) is an orally active cucurbitane-type triterpene glycoside. Momordicoside G selectively induces apoptosis of M1-like macrophages, without affecting M2-like macrophages. Momordicoside G reduces intracellular ROS levels and promotes autophagy. Momordicoside G also has anticancer activity, inhibiting the growth of cancer cell lines. Momordicoside G stimulates M2-associated lung injury repair and prevents inflammatory lung cancer injury .

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
タイトル			国或いは地域 *
お名前 *			組纖名 *
デパートメント *
メールアドレス *			製品名 *
製品番号			カスタマ需要量 *
電話番号 *
必ず会社名を記載ください。個人への返信は行いません。
備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店:

MedChemExpress Magic Cece

MedChemExpress: お問い合わせ; 会社紹介; 本社; ディストリビューター; 虚偽報告に関する声明; 採用情報

サービスとサポート: 技術サポート; サービス; オーダー情報; ご返品; 配送料&ポリシー; 知的財産に関する約束

技術資料: 無料サンプル・ポリシー; 文献; モル濃度計算機; 希釈計算機; 利用規約; 再構成計算機; 比活性計算機; DNA/RNA 配列の変換ツール

メルマガ登録

お名前
メール *

	Sorry, but the email address you supplied was invalid.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Copyright © 2013-2026 MedChemExpress. All Rights Reserved.: Site Map Privacy and Cookie Policy

Join with us